


# Novel Outcome Metric 'Complete Clot Ingestion' Presented at SNIS 2024 Conference by Dr. Robert Starke

*Dr. Robert Starke introduced the Complete Clot Ingestion (CCI) metric at SNIS 2024, highlighting the ALGO Smart Pump's potential in stroke thrombectomy.*

MIAMI, FL, USA, July 31, 2024

/EINPresswire.com/ -- Dr. [Robert Starke](#)

recently presented groundbreaking research at the Society of NeuroInterventional Surgery (SNIS) 2024 Conference in Colorado Springs, CO. His presentation introduced a novel outcome metric, Complete Clot Ingestion (CCI), aimed at enhancing the evaluation of success in thrombectomy procedures in acute ischemic stroke treatment.



**Conclusions**

- CCI **faster** (35.7 vs. 88.5 seconds)
- CCI **fewer distal emboli** (0% vs. 6.6%)
- **ALGO higher** rate of CCI (77% vs 37%)
- **ALGO faster** CCI (30.7 vs. 46.4 seconds)
- **ALGO ingests larger clots** (14.7mm vs. 9.9mm)
- ALGO higher CCI **across catheters sizes & companies**

UHealth  
UNIVERSITY OF MIAMI

Dr. Starke presenting at the 21st annual SNIS meeting in Colorado Springs, CO.

Today, the gold standard for stroke thrombectomy procedures is achieving radiographic reperfusion on the first pass, specifically TIC1 2c/3 (Thrombolysis in Cerebral Infarction). This is known as the first pass effect, or FPE. However, Dr. Starke's research suggests that this measure alone may be insufficient, as it might not account for unvisualized distal emboli that could occur even when TIC1 3 is achieved. The CCI metric provides a more comprehensive assessment, defined by the complete ingestion of the clot into the catheter or pump canister, with no external clot remnants.

“

The ALGO Smart Pump, with its Adaptive Pulsatile Aspiration (APA™) mode, has shown promise in achieving more complete clot removal, thereby potentially improving patient outcomes.”

*Dr. Robert Starke*

“We believe that the introduction of the Complete Clot Ingestion (CCI) metric represents a significant advancement in evaluating the success of thrombectomy

procedures,” said lead investigator Dr. Robert, Starke, Associate Professor of Clinical Neurosurgery, Neuroradiology and Neurosciences at the University of Miami Miller School of

Medicine and lead investigator on this study. "The ALGO Smart Pump, with its Adaptive Pulsatile Aspiration (APA™) mode, has shown promise in achieving more complete clot removal, thereby potentially improving patient outcomes. We are excited about the implications of this research and look forward to further clinical validation."

The study compared two thrombectomy pump devices: the ALGO Smart Pump ([Von Vascular Inc.](#), Sunrise, FL) and the ENGINE Pump (Penumbra Inc., Alameda, CA). Using an in vitro synthetic clot analog model, the research tested these devices in 360 thrombectomies across six catheter systems, focusing on CCI and the presence of distal emboli. In cases where CCI was achieved, there were zero instances of distal emboli, as compared with 7% distal emboli in cases where CCI was not achieved. The ALGO Smart Pump, featuring Adaptive Pulsatile Aspiration (APA™), works by novel mechanism that differs from conventional static or cyclical pumps. ALGO demonstrated superior performance in achieving higher CCI rates.

"At Von Vascular, we are thrilled to see the ALGO Smart Pump's Adaptive Pulsatile Aspiration (APA™) technology being recognized for its potential to enhance stroke thrombectomy," said [Manning Hanser](#), CEO of Von Vascular. "This study underscores the importance of innovative approaches in thrombectomy devices, and we are committed to advancing stroke treatment for better patient care."

Dr. Starke's research highlights the potential of the CCI metric as a valuable tool for assessing thrombectomy efficacy. The study's results indicate that the ALGO Smart Pump's APA™ mode is particularly effective in minimizing the risk of distal emboli. However, further clinical validation is necessary to confirm these findings.

About Von Vascular, Inc.

Von Vascular, Inc. is a leading medical device company dedicated to revolutionizing vascular health through innovative technologies. With a focus on improving patient outcomes and advancing the standard of care, Von Vascular is committed to delivering cutting-edge solutions that address unmet medical needs in the cardiovascular field. For more information, visit [vonvascular.io](#)

###

Dani Goldstein  
Von Vascular  
[Dani@vonvascular.io](mailto:Dani@vonvascular.io)

---

This press release can be viewed online at: <https://www.einpresswire.com/article/731571334>

EIN Presswire's priority is source transparency. We do not allow opaque clients, and our editors try to be careful about weeding out false and misleading content. As a user, if you see something we have missed, please do bring it to our attention. Your help is welcome. EIN Presswire, Everyone's Internet News Presswire™, tries to define some of the boundaries that are reasonable

in today's world. Please see our Editorial Guidelines for more information.

© 1995-2024 Newsmatics Inc. All Right Reserved.